Combination Therapy, Targeted Therapy
Approved for: NSCLC
Biomarker: BRAF
Trametinib (Mekinist) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used with dabrafenib. Trametinib is used only in patients whose cancer has a certain mutation in the BRAF gene.
